Stapled Peptides Could Protect Beneficial mRNA from Being Destroyed | Research

The takeaway

Researchers designed stapled peptides that block the machinery responsible for degrading mRNA, potentially opening a new therapeutic approach to preserve beneficial gene expression.

First-in-class
Stapled peptide inhibitors of mRNA deadenylation targeting the CCR4-NOT complex

What the researchers found

Stapled peptides successfully inhibited mRNA deadenylation by disrupting the NOT9 subunit of the CCR4-NOT complex, establishing a new strategy for preserving beneficial mRNA stability and translational activity.

Why it matters

While mRNA therapies have focused on silencing harmful genes, this is one of the first approaches to do the opposite — protect beneficial mRNA. Stapled peptides offer structural stability that regular peptides lack, making them viable drug candidates for this novel mechanism.

The numbers in context

- NIP-2 binding affinity: KD = 60.4 nM

- RNA binding inhibition: IC50 = 333 nM

- Cell permeability: EC50 = 2.44 microM (NIP-2), 0.34 microM (optimized NIP-2-H27A-N3)

- Intracellular mRNA stabilization demonstrated at 100 microM in HeLa cells

- 7-fold improvement in cell permeability with optimization

How the study worked

In vitro study involving rational design and synthesis of stapled peptides targeting the NOT9 subunit of the CCR4-NOT deadenylation complex, followed by biochemical and functional assays to assess mRNA stabilization.

Who was studied

In vitro biochemical assays and HeLa cell experiments. Structure-guided stapled peptide design targeting NOT9 subunit of CCR4-NOT complex.

What this study cannot tell us

In vitro study only — no in vivo or cellular data presented in abstract; selectivity for specific mRNA transcripts not demonstrated; pharmacokinetic properties of the stapled peptides unknown; far from clinical application.

How to read the evidence

Early-stage in vitro proof-of-concept. Demonstrates feasibility of the approach but requires extensive further development and validation.

When this study was published

Published in 2025, representing an emerging area at the intersection of peptide chemistry and RNA biology.

The bigger picture

This represents a paradigm shift in mRNA therapeutics — from destruction to preservation. If specific mRNAs could be selectively stabilized, it could treat conditions where beneficial proteins are underproduced, complementing existing mRNA and siRNA therapies.

Questions still open

Can these stapled peptides selectively stabilize specific mRNA transcripts rather than broadly inhibiting deadenylation?
What diseases might benefit from increased mRNA stability rather than mRNA silencing?
How would these peptides be delivered to target cells in a therapeutic setting?

Common questions

What is a stapled peptide?

A stapled peptide is a small protein fragment that has been chemically 'stapled' — cross-linked with a synthetic bridge — to lock it into a specific shape. This makes it more stable, better at binding its target, and more resistant to being broken down by the body.

Why would you want to protect mRNA from being destroyed?

Sometimes the body doesn't make enough of a beneficial protein because its mRNA instructions are degraded too quickly. If you could protect that mRNA, cells would produce more of the needed protein, potentially treating diseases caused by protein deficiency.

Read the original research

Stapled Peptides as Inhibitors of mRNA Deadenylation.

Angewandte Chemie (International ed. in English), 64(1), e202413911

View on PubMed ↗Publisher’s paper ↗

Citation

Pal, Sunit; Gordijenko, Ilja; Schmeing, Stefan; Biswas, Somarghya; Akbulut, Yasemin; Gasper, Raphael; 't Hart, Peter. (2025). Stapled Peptides as Inhibitors of mRNA Deadenylation.. Angewandte Chemie (International ed. in English), 64(1), e202413911. https://doi.org/10.1002/anie.202413911